Gonadorelin

ID: gonadorelin

Aliases: GnRH, LHRH

Type: compound

Route/form: injection; pulsatile pump context matters

Status: diagnostic_or_fertility_context_dependent

Evidence level: early human

Best data tier: early human

Support scope: human, review/regulatory

Source types: human_trial, review

Linked sources: 3

Broad outcomes: Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GnRH receptor agonist

Optimization domains

• fertility
• endocrine

Research basis

• Gonadorelin/GnRH is a real upstream HPG-axis intervention when delivered in a pulsatile pattern, with human HH literature supporting testosterone and spermatogenesis restoration in the right context.
• The strongest optimization relevance is fertility-axis restoration under medical monitoring, not direct gym performance.
• It maps cleanly against hCG/HMG because it asks the pituitary to release LH/FSH rather than replacing downstream gonadotropin activity.

Limits, risks, and missing evidence

• Delivery pattern is the pharmacology: continuous GnRH agonism can suppress gonadotropins rather than restore them.
• Casual injection schedules do not reproduce pulsatile pump therapy and should not be treated as equivalent.
• Fertility endpoints require semen analysis, gonadotropins, testosterone/estradiol, and testicular-volume context.

Risk flags

• hpg axis
• delivery pattern sensitive
• medical supervision
• fertility context

Linked papers, labels, and reviews

1. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism
   human_trial / pubmed_gonadorelin_hypogonadotropic_men_1986
   Pulsatile GnRH/gonadorelin physiology and treatment source in hypogonadotropic men.
2. Endotext: Hypogonadotropic hypogonadism and gonadotropin therapy
   review / ncbi_endotext_hh_gonadotropin_therapy
   Clinical review explaining pulsatile GnRH versus gonadotropin therapy and fertility endpoints.
3. Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism
   human_trial / pmc_hmg_gnrh_spermatogenesis_hh_2019
   Human HH comparison of pulsatile GnRH and HCG/HMG injection protocols for spermatogenesis-oriented endpoints.